| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5985305 | ORTHO MCNEIL JANSSEN | Sustained delivery of an active agent using an implantable system |
Jan, 2017
(7 years ago) | |
| US6156331 | ORTHO MCNEIL JANSSEN | Sustained delivery of an active agent using an implantable system |
Jan, 2017
(7 years ago) | |
| US5728396 | ORTHO MCNEIL JANSSEN | Sustained delivery of leuprolide using an implantable system |
Jan, 2017
(7 years ago) | |
| US6395292 | ORTHO MCNEIL JANSSEN | Sustained delivery of an active agent using an implantable system |
Jan, 2017
(7 years ago) | |
| US6132420 | ORTHO MCNEIL JANSSEN | Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems |
Jan, 2017
(7 years ago) | |
| US6235712 | ORTHO MCNEIL JANSSEN | Non-aqueous polar aprotic peptide formulations |
Jun, 2017
(6 years ago) | |
| US5932547 | ORTHO MCNEIL JANSSEN | Non-aqueous polar aprotic peptide formulations |
Jun, 2017
(6 years ago) | |
| US6124261 | ORTHO MCNEIL JANSSEN | Non-aqueous polar aprotic peptide formulations |
Jun, 2017
(6 years ago) | |
| US6113938 | ORTHO MCNEIL JANSSEN | Beneficial agent delivery system with membrane plug and method for controlling delivery of beneficial agents |
Jul, 2018
(5 years ago) | |
| US6375978 | ORTHO MCNEIL JANSSEN | Rate controlling membranes for controlled drug delivery devices |
Dec, 2018
(5 years ago) | |
Viadur is owned by Ortho Mcneil Janssen.
Viadur contains Leuprolide Acetate.
Viadur has a total of 10 drug patents out of which 10 drug patents have expired.
Expired drug patents of Viadur are:
- US5985305
- US6156331
- US5728396
- US6395292
- US6132420
- US6235712
- US5932547
- US6124261
- US6113938
- US6375978
Viadur was authorised for market use on 03 March, 2000.
Viadur is available in implant;implantation dosage forms.
Viadur can be used as method of treating a subject suffering from prostate cancer.
The generics of Viadur are possible to be released after 17 December, 2018.
Drugs and Companies using LEUPROLIDE ACETATE ingredient
Market Authorisation Date: 03 March, 2000
Treatment: Method of treating a subject suffering from prostate cancer
Dosage: IMPLANT;IMPLANTATION
VIADUR family patents
